GENMAB A/SGMABEarnings & Financial Report
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, Genmab K.K. in Tokyo, Japan, Genmab Germany GmbH in München, Germany and Genmab (Suzhou) Co., Ltd. in Suzhou, China. Genmab is listed on the Co...
GMAB Q2 2025 Key Financial Metrics
売上高
$925.0M
粗利益
$868.0M
営業利益
$360.0M
純利益
$336.0M
粗利益率
93.8%
営業利益率
38.9%
純利益率
36.3%
前年比成長
18.7%
EPS
$5.42
資金フロー
GENMAB A/S Q2 2025 Financial Summary
GENMAB A/S reported revenue of $925.0M (up 18.7% YoY) for Q2 2025, with a net profit of $336.0M (up 65.5% YoY) (36.3% margin). Cost of goods sold was $57.0M, operating expenses totaled $508.0M.
Key Financial Metrics
| Total Revenue | $925.0M |
|---|---|
| Net Profit | $336.0M |
| Gross Margin | 93.8% |
| Operating Margin | 38.9% |
| Report Period | Q2 2025 |
Revenue Breakdown
GENMAB A/S Q2 2025 revenue of $925.0M breaks down across 9 segments, led by Darzalex at $638.0M (69.0% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Darzalex | $638.0M | 69.0% |
| Kesimpta | $108.0M | 11.7% |
| Net Product Sales | $101.0M | 10.9% |
| Other | $28.0M | 3.0% |
| Tepezza | $20.0M | 2.2% |
| Reimbursement Revenue | $13.0M | 1.4% |
| Bio N Tech | $11.0M | 1.2% |
| Abb Vie | $5.0M | 0.5% |
| Milestone Revenue | $1.0M | 0.1% |
GENMAB A/S Quarterly Revenue & Net Profit History
GENMAB A/S quarterly results over the last 2 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 2025 | $925.0M | +18.7% | $336.0M | 36.3% |
| Q2 2024 | $779.0M | — | $203.0M | 26.1% |
損益計算書
| Q2 2024 | Q2 2025 | |
|---|---|---|
| 売上高 | $779.0M | $925.0M |
| 前年比成長 | N/A | 18.7% |
貸借対照表
| Q2 2024 | Q2 2025 | |
|---|---|---|
| 総資産 | N/A | $6.46B |
| 総負債 | N/A | $1.16B |
| 株主資本 | $4.45B | $5.30B |